RecruitingPhase 1NCT05943496

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
OHSU Knight Cancer Institute
Principal Investigator
Stephen E Spurgeon
OHSU Knight Cancer Institute
Intervention
Acalabrutinib(drug)
Enrollment
27 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2028

Study locations (1)

Collaborators

Oregon Health and Science University · Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05943496 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials